|Title:||Characterisation of endogenous Galectin-1 and -9 expression in monocyte and macrophage subsets under resting and inflammatory conditions||Authors:||Krautter, Franziska
Recio Cruz, Carlota Pilar
Hussain, Mohammed T.
Lezama, Danielle R.
Iqbal, Asif J.
|UNESCO Clasification:||3207 Patología
|Journal:||Biomedicine and Pharmacotherapy||Abstract:||Macrophages are key cells in both acute and chronic inflammatory settings. Their activation and function highly depends on the cytokines, chemokines and adhesion molecules that direct monocytes to infiltrate tissues, differentiate into macrophages, and finally lead to the clearance of such inflammatory signals. Galectins, β‐galactoside‐binding lectins, are differentially expressed by various immune cells, and some members of this family have been identified as regulators of leukocyte recruitment and activation. Galectin-1 (Gal-1) and galectin-9 (Gal-9) expression has been described in immune cells, but the specific molecular mechanisms by which they modulate the inflammatory response in macrophages/monocytes are not completely understood. In this study we sought to comprehensively characterise the expression profile of endogenous Gal-1 and Gal-9 in different murine and human monocyte/macrophage populations in response to different inflammatory stimuli. All subsets of murine and human macrophages expressed significant levels of Gal-1 and -9. Interestingly, murine bone marrow derived macrophages stimulated with M2 (pro-resolution) polarising agents preferentially upregulated Gal-1, while Gal-9 expression was upregulated by M1/pro-inflammatory stimulation. However, we observed differing results in human monocyte derived macrophages. Collectively, our findings report a differential expression pattern of endogenous Gal-1 and -9 in macrophage and monocyte subsets in response to a range of inflammatory stimuli. Future studies will endeavour to elucidate whether the galectins make attractive therapeutic targets or agents for regulating the inflammatory response.||URI:||http://hdl.handle.net/10553/74818||ISSN:||0753-3322||DOI:||10.1016/j.biopha.2020.110595||Source:||Biomedicine and Pharmacotherapy [ISSN 0753-3322], v. 130, 110595|
|Appears in Collections:||Artículos|
checked on Dec 24, 2022
checked on Dec 24, 2022
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.